BioTech

Centessa Prices Public Offering At $21.50 Per ADS

November 12, 2025 — 05:46 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Centessa Pharmaceuticals plc (CNTA) has priced its underwritten public offering of 11.63 million American Depositary Shares ("ADSs"), each representing one ordinary share, at $21.50 per ADS.

This clinical-stage biopharmaceutical company is pioneering a new class of therapies targeting orexin receptor 2 (OX2R) for neurological, neurodegenerative, and neuropsychiatric disorders.

The offering, which is scheduled to close on or about November 14, 2025, is expected to generate gross proceeds of approximately $250 million before deducting underwriting discounts and expenses.

The underwriters have a 30-day option to purchase up to an additional 1.74 million ADSs at the public offering price, less underwriting discounts and commissions.

CNTA has traded in the range of $9.60 - $25.42 in the last 1 year. The stock closed yesterday's trading at $22.54, up 0.94%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Centessa Prices Public Offering At $21.50 Per ADS

Tags

Latest Articles